| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
|
Lancet
|
2004
|
6.27
|
|
2
|
Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).
|
J Infect Dis
|
1995
|
4.60
|
|
3
|
Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection.
|
AIDS
|
2000
|
2.14
|
|
4
|
Incidence and progression rates of age-related maculopathy: the Rotterdam Study.
|
Invest Ophthalmol Vis Sci
|
2001
|
2.04
|
|
5
|
Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study.
|
Lancet
|
1998
|
1.88
|
|
6
|
Curcumin is an in vivo inhibitor of angiogenesis.
|
Mol Med
|
1998
|
1.81
|
|
7
|
Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma.
|
J Clin Microbiol
|
1996
|
1.75
|
|
8
|
Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring.
|
J Infect Dis
|
1998
|
1.67
|
|
9
|
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
|
J Infect Dis
|
2001
|
1.62
|
|
10
|
Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis.
|
J Infect Dis
|
1999
|
1.61
|
|
11
|
Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates.
|
Antimicrob Agents Chemother
|
1993
|
1.56
|
|
12
|
Agranulocytosis and aprindine.
|
Lancet
|
1976
|
1.41
|
|
13
|
Strong association between failure of T cell homeostasis and the syncytium-inducing phenotype among HIV-1-infected men in the Amsterdam Cohort Study.
|
AIDS
|
2000
|
1.35
|
|
14
|
Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons.
|
J Infect Dis
|
1999
|
1.32
|
|
15
|
Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo.
|
J Infect Dis
|
1997
|
1.23
|
|
16
|
Body mass index course in asymptomatic HIV-infected homosexual men and the predictive value of a decrease of body mass index for progression to AIDS.
|
J Acquir Immune Defic Syndr Hum Retrovirol
|
1998
|
1.03
|
|
17
|
Clioquinol-zinc chelate: a candidate causative agent of subacute myelo-optic neuropathy.
|
Mol Med
|
1998
|
1.01
|
|
18
|
Regression of AIDS-related Kaposi's sarcoma associated with clearance of human herpesvirus-8 from peripheral blood mononuclear cells following initiation of antiretroviral therapy.
|
AIDS
|
1998
|
0.98
|
|
19
|
Improvement of chronic diarrhoea in patients with advanced HIV-1 infection during potent antiretroviral therapy.
|
AIDS
|
1998
|
0.98
|
|
20
|
Ultranonlocality in time-dependent current-density-functional theory: application to conjugated polymers.
|
Phys Rev Lett
|
2002
|
0.96
|
|
21
|
Treatment of HIV infection. Tolerability of commonly used antiretroviral agents.
|
Drug Saf
|
1996
|
0.90
|
|
22
|
Risk of macular degeneration with statin use should be interpreted with caution.
|
BMJ
|
2001
|
0.88
|
|
23
|
Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents.
|
J Acquir Immune Defic Syndr Hum Retrovirol
|
1997
|
0.88
|
|
24
|
Presence of the variant mannose-binding lectin alleles associated with slower progression to AIDS. Amsterdam Cohort Study.
|
AIDS
|
1998
|
0.87
|
|
25
|
Vigilance and EEG power in rats: effects of potent inhibitors of the neuronal nitric oxide synthase.
|
Naunyn Schmiedebergs Arch Pharmacol
|
1997
|
0.84
|
|
26
|
Efficient inhibition of both syncytium-inducing and non-syncytium-inducing wild-type HIV-1 by lamivudine in vivo.
|
AIDS
|
1998
|
0.82
|
|
27
|
A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients.
|
AIDS
|
2000
|
0.81
|
|
28
|
A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). HIV Netherlands Australia Thailand Research Collaboration.
|
AIDS
|
2000
|
0.80
|
|
29
|
Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively.
|
J Clin Invest
|
1997
|
0.79
|
|
30
|
Sleep and nitric oxide: effects of 7-nitro indazole, inhibitor of brain nitric oxide synthase.
|
Brain Res
|
1996
|
0.79
|
|
31
|
Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine.
|
AIDS
|
2001
|
0.78
|
|
32
|
Effects of recombinant human granulocyte colony-stimulating factor on leucopenia in zidovudine-treated patients with AIDS and AIDS related complex, a phase I/II study.
|
Br J Haematol
|
1991
|
0.75
|
|
33
|
Platelet-derived growth factor increases plasminogen activator inhibitor-1 activity and mRNA in rat cultured vascular smooth muscle.
|
Ann N Y Acad Sci
|
1992
|
0.75
|
|
34
|
Pick-up and drop transfer of diamond nanosheets.
|
Nanotechnology
|
2015
|
0.75
|
|
35
|
Acute primary HIV-esophagitis.
|
Endoscopy
|
1990
|
0.75
|
|
36
|
[Agranulocytosis during use of aprindine].
|
Ned Tijdschr Geneeskd
|
1976
|
0.75
|
|
37
|
[Intervals in manic-depressive psychoses].
|
Wien Z Nervenheilkd Grenzgeb
|
1970
|
0.75
|
|
38
|
Reliability of tuberculin purified derivative skin testing and delayed-type hypersensitivity skin test anergy in HIV-infected homosexual men, at risk of tuberculosis.
|
AIDS
|
1999
|
0.75
|
|
39
|
Natural occupation numbers: when do they vanish?
|
J Chem Phys
|
2013
|
0.75
|
|
40
|
[Amsterdam duration of antiretroviral medication (ADAM)--study: induction-suppression treatment in HIV-I infection, preliminary results].
|
Ned Tijdschr Geneeskd
|
1998
|
0.75
|
|
41
|
A physical model for the longitudinal polarizabilities of polymer chains.
|
J Chem Phys
|
2005
|
0.75
|